This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

AC Globulin Deficiency / Factor V DeficiencyAC글로불린결핍 (에이씨글로불린결핍증)

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: D68.2 | Special Copayment Reduction: V009 (rare disease, 10% copayment for 5 years after registration)
B. SynonymsParahemophilia, Parahemophilia, Factor V deficiency, proaccelerin deficiency, Owren disease, Labile factor deficiency
C. Adult onsetLikelihood of first presentation in adulthood not low — severe FV deficiency is diagnosed in the neonatal period to childhood; mild cases may be discovered in adulthood through excessive bleeding after surgery
1. HistoryOwren's discovery of AC globulin in 1947 and the history of the historical names used before it was named factor V
2. CausesDecreased plasma FV level or function due to pathogenic variants of the F5 gene (1q24.2)
3. GeneticsF5 gene at 1q24.2, autosomal recessive; fundamental difference from FV Leiden
4. EpidemiologyRare bleeding disorder affecting about 1 in 1 million people
5. PathophysiologyRole of FVa in the prothrombinase complex and hemostatic failure in the common pathway
6. SymptomsMucosal bleeding, heavy menstrual bleeding, postoperative bleeding; spontaneous joint bleeding is rare
7. SignsProlongation of both PT and APTT, normal TT, reduced FV activity
8. ScreeningProlongation of both PT and APTT + FV measurement after excluding vitamin K deficiency and liver disease
9. DiagnosisFV one-stage activity assay, mixing study, F5 gene analysis
10. TreatmentFFP, platelet transfusion (platelets are rich in FV), tranexamic acid
11. PrognosisGood in mild cases; risk of intracranial hemorrhage in severe cases, but overall milder than hemophilia A
12. PreventionPreoperative FFP replacement, genetic counseling
13. ReferencesOwren PA (1947) Lancet … and 11 other papers

1. History

Owren's 1947 discovery: the origin of the name AC globulin

The name AC globulin was first used by the Norwegian hematologist Paul Arnesley Owren (1905–1990) in a paper published in Lancet in 1947. While studying a young female patient in Scandinavia, Owren discovered a third coagulation abnormality distinct from both hemophilia A·B and thrombin deficiency. He concluded that this abnormality resulted from a deficiency of a plasma component that 'accelerates' the coagulation process, and named this factor Accelerator globulin, or AC globulin for short.

Owren's paper was also the first report in which he used the term 'proaccelerin.' That is, he hypothesized that proaccelerin, which exists in plasma as an inactive precursor, is activated to become 'true accelerin.' Derived from this patient's name, the disease is also called 'Owren disease (Owren's disease).' Owren gained great renown in the Norwegian medical community for this research.

Confusion over names before the Roman numeral nomenclature of coagulation factors

Until the early 1950s, different research groups used different names for the same factor. Quick's group in the United States called this factor the 'labile factor,' reflecting its tendency to degrade rapidly during blood storage (it is barely detectable in serum). This contrasts with FIX, which was then called the 'stable factor.' When the international nomenclature committee introduced the Roman numeral system in 1960, AC globulin was officially designated Factor V (FV), and proaccelerin, proposed by Owren, was also recognized as one of its official names.

Modern understanding of FV and the concept of parahemophilia

Because FV deficiency shows a clinical course similar to, but not identical with, hemophilia A·B, the name 'parahemophilia' began to be used from the 1960s. The complete primary structure of the FV molecule was determined by Jenny et al. in 1986, and in 1994 the FV Leiden (p.Arg534Gln, formerly Arg506Gln) variant was identified as the cause of activated protein C (APC) resistance. FV Leiden is a gain-of-function variant that causes the opposite phenotype to FV deficiency—a thrombotic tendency—and is very common in European populations. FV deficiency research and FV Leiden research have become an important teaching case in coagulation science, in that they share a common molecular background yet point in clinically opposite directions.

2. Causes

F5 gene variants and reduced FV synthesis

The direct cause of AC globulin deficiency (FV deficiency) is pathogenic variants in the F5 gene (chromosome 1q24.2). The F5 gene consists of 25 exons and encodes the FV protein of 2,224 amino acids. Various variant types have been reported, including missense, nonsense, splicing, and small deletions/insertions, and more than about 200 pathogenic variants have been registered to date. FV is stored in substantial amounts not only in plasma but also within platelets (α-granules), and platelet-derived FV accounts for about 20% of total FV. This supports the role of platelet transfusion in treatment strategy.

Complex FV deficiency: combined FV·FVIII deficiency

A special form of FV deficiency is combined FV and FVIII deficiency (F5F8D). It is caused not by the F5 or F8 genes themselves but by variants in the LMAN1 (18q21.3) or MCFD2 (2p21) genes, which encode proteins required for the intracellular transport of FV and FVIII. F5F8D is a separate clinical entity but may be included in the D68.2 category. It is clinically important to distinguish it from AC globulin deficiency (D68.2, parahemophilia), which is an isolated deficiency of FV alone.

3. Genetics

Structure of the F5 gene and domains of the FV protein

The F5 gene is located on chromosome 1q24.2, is about 80 kb long, and consists of 25 exons. The FV protein (2,224 amino acids) encoded by this gene has an A1-A2-B-A3-C1-C2 domain structure. The B domain shares similarity with the B domain of FVIII and is removed during activation by thrombin. Activated FVa is a two-chain structure in which A1-A2 (heavy chain) and A3-C1-C2 (light chain) are linked by calcium ions. The Arg306 and Arg506 cleavage sites for APC (activated protein C) are located in the A1 and A2 domains, respectively.

Genetic contrast between autosomal recessive inheritance and FV Leiden

FV deficiency is inherited in an autosomal recessive manner. This means that, unlike the X-linked inheritance of hemophilia A·B, it occurs equally in males and females. Heterozygous carriers have FV activity of 40–60% of normal and are mostly asymptomatic, but have a mildly increased bleeding risk during surgery or delivery. Severe deficiency occurs with homozygous or compound heterozygous variants.

The FV Leiden variant (p.Arg534Gln) is the opposite of FV deficiency. This gain-of-function variant prevents APC from normally inactivating FVa, so that FVa activity persists excessively and causes a thrombotic tendency. FV Leiden is the most common cause of inherited thrombophilia in European Caucasian populations (heterozygous prevalence about 5%), a clinical context entirely different from FV deficiency. Both conditions are associated with the F5 gene, but their phenotypes are completely opposite.

4. General epidemiology

Prevalence and geographic distribution

FV deficiency (parahemophilia, AC globulin deficiency) is a rare bleeding disorder with a worldwide prevalence of about 1 in 1 million. According to the WFH Global Survey, the number of registered patients worldwide is in the thousands. Relatively more severe cases are reported in Iran, India, Pakistan, and some regions of Africa, where consanguineous marriage is common. In a study conducted in Iran, FV deficiency was recorded as one of the relatively common types within the D68.2 category.

Status in Korea

There are no precise prevalence statistics for FV deficiency in Korea. FV deficiency is estimated to account for a certain proportion of patients registered under D68.2 in Health Insurance Review & Assessment Service (HIRA) data, but separate statistics by individual factor deficiency type are not published. There are sporadic case reports from tertiary general hospitals, including mild adult patients discovered incidentally through preoperative findings of prolonged PT and APTT. Systematic research on Korean-specific F5 gene variants is still lacking.

5. Pathophysiology

Role of FVa in forming the prothrombinase complex

In the common pathway of the coagulation cascade, FVa is an essential component of the prothrombinase complex. This complex consists of FXa (catalytic subunit), FVa (cofactor subunit), calcium ions, and an anionic phospholipid membrane (the surface of activated platelets). FVa binds to FXa and acts as a crucial cofactor that increases the efficiency of prothrombin cleavage by FXa by more than about 10,000-fold. In FV deficiency, formation of this complex is impaired, thrombin generation is markedly reduced, and ultimately fibrin formation and platelet activation become insufficient, resulting in hemostatic failure.

Platelet FV and clinical heterogeneity

One reason bleeding tendency varies among patients with plasma FV deficiency is that the amount of platelet FV (stored in platelet α-granules) may differ between individuals. In some patients, even when plasma FV activity is extremely low, platelet-derived FV compensates for local hemostasis, so the bleeding tendency may be mild. In contrast, when platelet FV stores are also reduced, the bleeding tendency is more severe. For this reason, platelet transfusion is recommended together with FFP for severe bleeding, and platelet transfusion is significant not merely for platelet replacement but also for supplying FV.

6. Symptoms

Mucosal bleeding and postoperative bleeding

The most common symptom of FV deficiency (AC globulin deficiency) is mucosal bleeding. Nosebleeds (epistaxis), gum bleeding, and heavy menstrual bleeding (in women) are frequent, and excessive bleeding occurs after tooth extraction or minor surgery. Unlike hemophilia A, spontaneous joint bleeding is rare, but intra-articular bleeding has been reported in severe deficiency (FV activity <1%). Gastrointestinal bleeding, hematuria, and soft-tissue hematomas may also occur.

Intracranial hemorrhage and neonatal presentation in severe deficiency

Intracranial hemorrhage is not uncommon in patients with severe FV deficiency. According to EN-RBD cohort data, intracranial hemorrhage was reported in about 10% of patients with severe FV deficiency. In the neonatal period, it may first be diagnosed through umbilical cord bleeding. Female patients have a high risk of postpartum hemorrhage at delivery, and there are reports of an increased risk of spontaneous miscarriage during pregnancy. In male patients, prolonged bleeding after circumcision or hematoma after vaccination may be the initial symptom.

7. Signs

Simultaneous prolongation of PT and APTT

The most characteristic coagulation test finding of FV deficiency (AC globulin deficiency) is prolongation of both PT (prothrombin time) and APTT (activated partial thromboplastin time). Because FV is located in the common pathway, abnormalities appear in both the extrinsic (PT test) and intrinsic (APTT test) pathways. Thrombin time (TT) and fibrinogen quantification are normal. Simultaneous prolongation of PT and APTT also occurs in deficiencies of common pathway factors (FV, FX, FII) or in combined pathway abnormalities (vitamin K deficiency, liver disease, anticoagulant use), so differentiation is required.

Mixing study and FV-specific activity assay

When a mixing study is performed as a follow-up test, PT and APTT are corrected in FV deficiency upon 1:1 mixing with normal plasma. Next, the FV level is quantified with the FV one-stage activity assay. The FV activity assay uses FV-deficient plasma as substrate and is measured by the dilution curve method. Concurrent measurement of FV antigen (immunoassay) allows differentiation between quantitative deficiency and the dysfunctional type (dysfunctional FV). The presence of an inhibitor (autoantibody) is suspected when correction fails in the mixing study and is confirmed by the FV-specific inhibitor titer (Bethesda assay).

8. Screening

Differential diagnosis algorithm for simultaneous prolongation of PT and APTT

When PT and APTT are both prolonged in a preoperative or bleeding evaluation, the differential approach proceeds in the following order. First, vitamin K deficiency is excluded (in vitamin K deficiency, the vitamin K-dependent factors FII, FVII, FIX, and FX are all decreased and are corrected after vitamin K administration). Next, liver dysfunction is excluded (multiple factors are decreased in hepatocellular coagulopathy). Heparin contamination and anticoagulant use are also excluded. After all of these are excluded, if a selective decrease in FV is confirmed by the FV activity assay, AC globulin deficiency (FV deficiency) is diagnosed.

Differentiation from acquired FV inhibitors

Acquired FV deficiency, in which FV inhibitors develop after transfusion or after antibiotic (especially ampicillin) administration, is rarely reported. In this case, differentiation from congenital FV deficiency is required. When an acquired inhibitor is present, PT and APTT are not corrected in the mixing study, and this is confirmed by measurement of the FV inhibitor titer. Taking a family history and understanding the circumstances of onset are important for differentiation.

9. Diagnosis

Stepwise diagnostic approach

Confirmation of AC globulin deficiency (FV deficiency) is done in steps. Step 1: confirm simultaneous prolongation of PT and APTT with normal TT. Step 2: exclude vitamin K deficiency, liver disease, and anticoagulant use. Step 3: differentiate factor deficiency from an inhibitor with a mixing study. Step 4: quantify the FV level with the FV one-stage activity assay. Step 5: if necessary, confirm pathogenic variants with F5 gene Sanger analysis or an NGS-based coagulation factor panel.

Severity classification

According to WFH and EN-RBD criteria, FV activity <1% is classified as severe, 1–10% as moderate, and >10% as mild. In patients with severe deficiency, prophylactic measures are essential for surgery, trauma, and delivery. Because mild patients can bleed even with minor surgery, preoperative confirmation of FV activity is necessary. Platelet FV levels are difficult to measure with standard clinical tests, so the individual bleeding history becomes an important clinical indicator.

10. Treatment

Fresh frozen plasma and platelet transfusion

The main treatment for FV deficiency (AC globulin deficiency) is fresh frozen plasma (FFP). FFP supplies all coagulation factors including FV and is used for treatment of bleeding and preoperative prophylaxis. Generally, 15–20 mL/kg of FFP can raise FV activity to 15–25%, which is the minimum target level required for hemostasis. Currently there is no licensed FV-specific concentrate, so FFP is the only source of FV.

Platelet transfusion is an important adjunctive treatment in FV deficiency. FV is abundantly stored in platelet α-granules, and platelet transfusion supplies FV directly to sites of local clot formation. In particular, combined use of FFP and platelet transfusion is recommended in serious bleeding situations such as intracranial hemorrhage or after major surgery. When an acquired FV inhibitor is present, correction is not possible with FFP alone, so rFVIIa (NovoSeven) bypassing therapy is considered.

Tranexamic acid and adjunctive treatment

Tranexamic acid is an antifibrinolytic agent that is useful as an adjunct in FV-deficient patients in whom mucosal bleeding is the main problem. It can be used topically or systemically for tooth extraction, oral surgery, nosebleeds, and heavy menstrual bleeding. Oral contraceptives or intrauterine devices are effective in reducing bleeding in female FV-deficient patients with heavy menstrual bleeding. Specific prophylaxis guidelines for FV deficiency have not yet been established, and an individualized treatment plan tailored to each patient's bleeding history and clinical situation is needed.

11. Prognosis

Differences in prognosis by severity

The prognosis of AC globulin deficiency (FV deficiency) varies greatly depending on severity and access to treatment. Patients with mild deficiency (FV activity >10%) have no particular problems in daily life, and hemostasis is achievable with appropriate FFP administration during surgery or trauma. In moderate and severe deficiency, there is a risk of spontaneous bleeding and intracranial hemorrhage, but it tends to be milder overall than severe cases of hemophilia A. According to studies based on the EN-RBD database, the overall bleeding severity of FV-deficient patients is intermediate compared with FVII deficiency or FXIII deficiency.

Long-term management and quality of life

Because there is currently no FV-specific concentrate, patients with FV deficiency are limited to receiving FFP each time bleeding occurs. Repeated FFP administration carries risks of transfusion-related viral infection, alloimmunization, and circulatory overload. Because FV deficiency does not cause arthropathy like hemophilia A·B, the risk of long-term motor dysfunction is low. In female patients, normal childbirth is possible with appropriate management of pregnancy and delivery.

12. Prevention

Preoperative prophylactic FFP administration

In FV-deficient patients, before planned surgery or invasive procedures, FFP should be administered to correct FV activity to at or above the target level (15–20% for minor surgery, 25% or more for major surgery). Because the half-life of FV from FFP is about 12–36 hours, additional doses may be needed on the day of surgery and for several days after major surgery. For minor procedures such as tooth extraction, prior administration of tranexamic acid and application of topical hemostatic agents can sometimes manage bleeding without FFP.

Genetic counseling and prenatal care

Genetic counseling and carrier testing are recommended for siblings, children, and potential spouses of patients with FV deficiency. When both parents of a patient are heterozygous carriers, there is a 25% risk with each pregnancy. For pregnant women with FV deficiency, a multidisciplinary delivery plan including a plan for FFP administration before delivery is essential. When a newborn is at high risk of FV deficiency, coagulation tests are performed immediately after birth so that early diagnosis and treatment can take place.


13. References

  1. Owren PA. The coagulation of blood: investigations on a new clotting factor. Acta Med Scand Suppl. 1947;194:1–327.
  2. Owren PA. Parahaemophilia: haemorrhagic diathesis due to absence of a previously unknown clotting factor. Lancet. 1947;1(6449):446–448.
  3. Asselta R, Peyvandi F. Factor V deficiency. Semin Thromb Hemost. 2009;35(4):382–389.
  4. Peyvandi F, Palla R, Menegatti M, Mannucci PM. Introduction: rare coagulation deficiencies. Haemophilia. 2012;18(Suppl 4):1–2.
  5. Duckers C, Simioni P, Spiezia L, et al. Low plasma levels of tissue factor pathway inhibitor in patients with congenital factor V deficiency. Blood. 2008;112(8):3615–3623.
  6. Lak M, Sharifian R, Peyvandi F, Mannucci PM. Symptoms of inherited factor V deficiency in 35 Iranian patients. Br J Haematol. 1998;103(4):1067–1069.
  7. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64–67.
  8. Jenny RJ, Pittman DD, Toole JJ, et al. Complete cDNA and derived amino acid sequence of human factor V. Proc Natl Acad Sci USA. 1987;84(14):4846–4850.
  9. Cines DB, Blanchette VS. Immune thrombocytopenic purpura. N Engl J Med. 2002;346(13):995–1008. [Reference related to FV antibodies]
  10. Wheby MS, Pemberton JH. Congenital FV deficiency (parahemophilia): a review. Am J Med Sci. 1966;252(2):193–199.
  11. Huang JN, Koerper MA. Factor V deficiency: a concise review. Haemophilia. 2008;14(6):1164–1169.
  12. Tabibian S, Motlagh H, Naderi M, et al. An overview of congenital factor V deficiency. Blood Coagul Fibrinolysis. 2019;30(2):39–46.